PCM
ARTV

Prelude Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Prelude Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,691
Closed -$45.9K – 1653
2025
Q4 		$45.9K Sell
10,691
-3,611
-25% -$13.6K ﹤0.01% 1240
2025
Q3 		$41K Buy
+14,302
New +$38.3K ﹤0.01% 1111

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Prelude Capital Management's ARTV Position: Q1 2026 in Review

Prelude Capital Management sold out of Artiva Biotherapeutics (ARTV) in Q1 2026, closing a stake of 10,691 shares — an estimated $45.9K sold.

Prelude Capital Management first reported a position in ARTV in Q3 2025 and held it in 2 quarters. The position peaked at $45.9K in Q4 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Prelude Capital Management reported no remaining Artiva Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 10,691 Artiva Biotherapeutics shares in Q1 2026, an estimated $45.9K.
  • Prelude Capital Management first reported a position in Artiva Biotherapeutics in Q3 2025 and held it in 2 quarters.
  • Prelude Capital Management's Artiva Biotherapeutics position peaked at $45.9K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.